252 related articles for article (PubMed ID: 19017757)
1. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
[TBL] [Abstract][Full Text] [Related]
2. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
[TBL] [Abstract][Full Text] [Related]
3. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
4. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
[TBL] [Abstract][Full Text] [Related]
5. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
[TBL] [Abstract][Full Text] [Related]
6. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
[TBL] [Abstract][Full Text] [Related]
7. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer.
Truran PP; Johnson SJ; Bliss RD; Lennard TW; Aspinall SR
World J Surg; 2014 Nov; 38(11):2845-54. PubMed ID: 25002250
[TBL] [Abstract][Full Text] [Related]
8. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
[TBL] [Abstract][Full Text] [Related]
9. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
[TBL] [Abstract][Full Text] [Related]
10. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
[TBL] [Abstract][Full Text] [Related]
11. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
12. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
[TBL] [Abstract][Full Text] [Related]
13. Loss of parafibromin expression in a subset of parathyroid adenomas.
Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
[TBL] [Abstract][Full Text] [Related]
14. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
17. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
[TBL] [Abstract][Full Text] [Related]
18. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease.
Tominaga Y; Tsuzuki T; Matsuoka S; Uno N; Sato T; Shimabukuro S; Goto N; Nagasaka T; Uchida K
World J Surg; 2008 May; 32(5):815-21. PubMed ID: 18338208
[TBL] [Abstract][Full Text] [Related]
19. Understanding the genetic basis of parathyroid carcinoma.
Gill AJ
Endocr Pathol; 2014 Mar; 25(1):30-4. PubMed ID: 24402736
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis.
Hu Y; Liao Q; Cao S; Gao X; Zhao Y
Endocrine; 2016 Dec; 54(3):612-619. PubMed ID: 27250989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
